@prefix this: . @prefix sub: . @prefix np: . @prefix pav: . @prefix rdf: . @prefix infores: . @prefix xsd: . @prefix orcid: . @prefix rdfs: . @prefix biolink: . @prefix prov: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubInfo; a np:Nanopublication . } sub:assertion { a biolink:DiseaseOrPhenotypicFeature; rdfs:label "COVID-19"; biolink:category biolink:DiseaseOrPhenotypicFeature . sub:_1 rdf:object ; rdf:predicate biolink:treats; rdf:subject ; a biolink:Association; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:Association; biolink:publications . sub:_2 rdf:object ; rdf:predicate biolink:treats; rdf:subject ; a biolink:Association; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:Association; biolink:publications . sub:_3 rdf:object ; rdf:predicate biolink:interacts_with; rdf:subject ; a biolink:Association; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:Association; biolink:publications . } sub:provenance { sub:assertion prov:generatedAtTime "2022-10-13T13:46:07.779203"^^xsd:dateTime; prov:wasAttributedTo orcid:0000-0002-3668-2627; prov:wasQuotedFrom " Etesevimab in combination with bamlanivimab is used to treat mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients, including neonates, with positive results of direct SARS-CoV-2 viral testing. This combination regimen is also used for post-exposure prophylaxis of COVID-2019 in unvaccinated or immunocompromised adults." . biolink: pav:version "2.3.0" . } sub:pubInfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIIBIjANBgkqhkiG9w0BAQEFAAOCAQ8AMIIBCgKCAQEApdULbl+/+pkVlq0fAzWmzfgIb+XMuQPKHMDVzUTWCZBjLfzORll42ptr52e4w7tTYkUKrBsQbx8lkjZWAlWiyh+xIK0oLFSdYRSt63kgiyRYBUOR+spcgmofb7f6JyftArPVTKhsWOMt/mcyNG9qc3lw8B/xuPmLteUWO33xWhfXQreTw1lsGUkZ1j4cB4X9HIuI20ktLYLCXaBauNHEJZ4qp6/Q2ATsJcw8tg7aRmFKXhrjM9maZ2+0cMg0Jpmn2UnDlPKXEA6Qq+qnvvQt8KFjIzP9FTMyvrWl8tTd0NCmS9VpooZJQ8We1lGMPXg5bMbe/bVkTf70fbFMf0RKrQIDAQAB"; npx:hasSignature "Nwm+TCfPueg/dGV/alO9K7tT3DhhzIfpBJDy2D4i5o644+Zf9imi0TddHr1zvReNVhdCV4cSlesHS74yeeiCaZ+UrSA5v9xUQ2FIW8RBuWH1BXnNfoDhzzZ0qfOn4LWTojvgC3SCd5BqhhbxVRLEwN56zoZ6hDugQ0UeNcFFc10+3O0LrFFsLMvWIODzjPyX3XLRIpGti0Wmsf5WrCLkIS3MAyu4aMxqK/kueJV68nsdI6poCFopqxpnSZSewdYea/JznU6zc+KZrJvTB1swL8MiPozfBe4h01Y5AIdC1aKynFCDh0vDA4ushOBpSn2XdUJheQ5saNdsJYs8PKSk2A=="; npx:hasSignatureTarget this: . this: prov:generatedAtTime "2022-10-13T13:46:07.779203"^^xsd:dateTime; prov:wasAttributedTo orcid:0000-0002-3668-2627 . }